PSB114 (QLP2117 in China) is a glycoengineered anti-CCR8 antibody designed to selectively deplete CCR8⁺ regulatory T cells (Tregs) that suppress immune responses within the tumor microenvironment. By targeting these tumor-associated Tregs—while sparing healthy tissues—PSB114 aims to enhance antitumor immunity with improved safety and specificity.
Preclinical studies demonstrated potent, Fc-mediated cytolytic activity, strong intratumoral Treg depletion, and synergy with PD-(L)1 blockade, resulting in improved tumor control and survival. These findings support PSB114 as a promising, highly selective immunotherapy designed to remodel the tumor microenvironment and boost response to cancer treatment.
Clinical development, led by our partner Qilu Pharmaceutical Co., Ltd., is ongoing in Phase Ib/II trials in China. Early clinical data have shown a favorable safety profile, dose-dependent pharmacodynamics, and biomarker evidence consistent with target engagement and immune activation.
Regulatory status: IND cleared by NMPA in China in 2023; Phase Ib/II clinical trials are ongoing.
